Biotech Investor News: (OTCQB: LAST) Portfolio Company, Sanguine BioSciences, Appoints Leader in Genomic and Biomarker Research to Scientific Advisory Board

SANTA MONICA, CA - April 10, 2012 (Investorideas.com Newswire) - Los Angeles Syndicate of Technology, Inc. ( OTCQB: LAST), a publicly-traded venture fund and technology incubator, is pleased to announce that its portfolio company, Sanguine BioSciences, Inc. ("Sanguine"), has appointed Dr. Timothy J. Triche, MD, PhD to Sanguine's Scientific Advisory Board. Sanguine Biosciences, Inc., an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines, was developed in LAST's technology incubator.

"We are pleased to announce Professor Triche's appointment to our Scientific Advisory Board," said Brian Neman, Sanguine's Chairman and Chief Executive Officer. "Dr. Triche has been a leader in genomic and biomarker research for decades, and provides the company with valuable strategic insight as the company is poised to begin digitizing biological and clinical data within its bio-repository."

Professor Timothy J. Triche, of the Center for Personalized Medicine (CPM) at Children's Hospital Los Angeles / University of Southern California, has more than 40 years of experience in Pathology and Laboratory Medicine. As the Director of the CPM, Dr. Triche coordinates, supports, and expands the hospital's basic and translational research objectives in genomics, proteomics, bioinformatics, molecular genetics, molecular microbiology and cytogenetics. Dr. Triche formerly held the position of director of Specialized Diagnostics, Pathology, at the National Institutes of Health and section chief in the Laboratory of Pathology at the National Cancer Institute of the National Institutes of Health, from 1975 to 1988.

Dr. Triche has authored over 188 peer-reviewed publications, 176 abstracts and 39 book chapters and his research has been funded by major organizations such as the National Cancer Institute, the Whittier Foundation, the Department of Energy, and the Department of Defense.

About Los Angeles Syndicate of Technology - www.last.vc

Los Angeles Syndicate of Technology, Inc. (OTC: LAST) is a publicly traded Business Development Company (BDC) operating as a venture fund and technology incubator that creates, builds, and invests in web and mobile technology companies. LAST develops digital media, social networking, and life sciences products in its technology incubator, and has a portfolio of six companies at different stages of development. LAST's mission is to foster technology innovation in Los Angeles by partnering with the most talented entrepreneurs of southern California and providing them with the capital, supp ort and tools to bring their ideas to market and commercialize their products.

About Sanguine Biosciences, Inc. - sanguinebio.com

Sanguine Biosciences, Inc. ("Sanguine") is an international supplier of DNA data and bio-specimen to research organizations for the development of personalized medicines.Sanguine provides highly viable primary human cells and tissues to both the academic and industrial life science research communities through a new direct-to-patient platform. The current product offering spans customers' needs in the In Vitro Research & Development stage of Drug Development. Sanguine's vision is to develop into the global leader in high quality cells and tissues for life science research and development.

Forward-Looking Statements

Statements included in this release related to Los Angeles Syndicate of Technology, Inc. and its portfolio companies constitute or may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the inherent uncertainty of investing in early-stage technology companies, the technological and financial difficulties inherent in these activities, and the Company's ability to estimate accurately net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the Securities and Exchange Commission.

Contact Information

Contact:
Los Angeles Syndicate of Technology, Inc.
Bryce Knight
(310) 694-0640

www.last.vc

Published at Investorideas.com Newswire

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure- Investorideas.com and its affiliate news and email partners was compensated three thousand for the distribution and publication of company news .

www.InvestorIdeas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894